Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - bupropion hydrochloride - tablets prolonged release - bupropion hydrochloride 150 mg - bupropion - bupropion - zyban is indicated as an aid to smoking cessation in combination with motivational support in nicotine-dependent patients.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - bupropion hydrochloride - tablets - bupropion hydrochloride 150 mg - bupropion - bupropion - wellbutrin xr is indicated for the treatment of major depressive episodes.following satisfactory response, continuation with wellbutrin xr therapy is effective in preventingrelapse.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - bupropion hydrochloride - tablets - bupropion hydrochloride 300 mg - bupropion - bupropion - wellbutrin xr is indicated for the treatment of major depressive episodes.following satisfactory response, continuation with wellbutrin xr therapy is effective in preventingrelapse.

United Kingdom - English - myHealthbox

mercury pharmaceuticals limited - gliclazide - modified-release tablet - 30mg - sulphonamides, urea derivative - it is indicated in adults for treatment of non-insulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

United Kingdom - English - myHealthbox

mercury pharmaceuticals limited - gliclazide - modified-release tablet - 60mg - sulphonamides, urea derivative - it is indicated in adults for treatment of non-insulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - flumetsulam - water dispersible granule - flumetsulam pyrimidine-sulfonamide active 800.0 g/kg - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - gabapentin, quantity: 600 mg - tablet - excipient ingredients: hyprolose; poloxamer; purified talc; magnesium stearate; crospovidone; mannitol - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic drugs.,gabapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - gabapentin -

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; maize starch; lactose monohydrate - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium starch glycollate; maize starch; lactose monohydrate; microcrystalline cellulose - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).